Evidence map›Paper›PMID 32368498›Full record

ArticleUrology case reports2020

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib.

Akihiro Yoshimura, Wataru Nakata, Gaku Yamamichi, Go Tsujimura, Yuichi Tsujimoto, Mikio Nin, Masao Tsujihata

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Akihiro YoshimuraDepartments of Urology, Osaka Rosai Hospital, 1179-3 Nagasone, Kitaku, Sakai City, Osaka, 591-8025, Japan.
Wataru NakataDepartments of Urology, Osaka Rosai Hospital, 1179-3 Nagasone, Kitaku, Sakai City, Osaka, 591-8025, Japan.
Gaku YamamichiDepartments of Urology, Osaka Rosai Hospital, 1179-3 Nagasone, Kitaku, Sakai City, Osaka, 591-8025, Japan.
Go TsujimuraDepartments of Urology, Osaka Rosai Hospital, 1179-3 Nagasone, Kitaku, Sakai City, Osaka, 591-8025, Japan.
Yuichi TsujimotoDepartments of Urology, Osaka Rosai Hospital, 1179-3 Nagasone, Kitaku, Sakai City, Osaka, 591-8025, Japan.
Mikio NinDepartments of Urology, Osaka Rosai Hospital, 1179-3 Nagasone, Kitaku, Sakai City, Osaka, 591-8025, Japan.
Masao TsujihataDepartments of Urology, Osaka Rosai Hospital, 1179-3 Nagasone, Kitaku, Sakai City, Osaka, 591-8025, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Target agents such as tyrosine kinase inhibitors have improved renal cell carcinoma (RCC) patient outcomes. However, complete remission (CR) with target agents is rare. Furthermore, CR of bone metastasis is much less common. We report a case of CR in bone and lung metastatic RCC. Radical nephrectomy was performed first, and clear cell RCC was diagnosed. Thereafter, sunitinib was started, and bone and lung metastases resolved entirely after 8 months of treatment. Sunitinib therapy was discontinued after 2 years because of the adverse event of proteinuria. However, the patient has remained in CR for over 1 year after sunitinib cessation.

Indexed as

Bone metastasisComplete responseRenal cell carcinomaSunitinib

Identifiers

PMID32368498
PMCPMC7184521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.